Company Description
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements.
It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands.
Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
| Country | United States |
| Founded | 2022 |
| IPO Date | May 4, 2023 |
| Industry | Household & Personal Products |
| Sector | Consumer Staples |
| Employees | 22,000 |
| CEO | Kirk Perry |
Contact Details
Address: 1 Kenvue Way Summit, New Jersey 07901 United States | |
| Phone | 908-874-1200 |
| Website | kenvue.com |
Stock Details
| Ticker Symbol | KVUE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 1944048 |
| CUSIP Number | 49177J102 |
| ISIN Number | US49177J1025 |
| Employer ID | 88-1032011 |
| SIC Code | 2844 |
Key Executives
| Name | Position |
|---|---|
| Kirk L. Perry | Chief Executive Officer and Director |
| Meredith Stevens | Chief Operations Officer |
| Amit Banati | Chief Financial Officer |
| Heather R. Howlett | Chief Accounting Officer |
| Michael Wondrasch | Chief Technology and Data Officer |
| Dr. Caroline Tillett Ph.D. | Chief Scientific Officer |
| Sofya Tsinis | Head of Investor Relations |
| Matthew Orlando | General Counsel |
| Jonathan Halvorson | Chief Digital and Marketing Officer |
| Luani Alvarado | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | 8-K | Current Report |
| Jan 29, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 425 | Filing |
| Jan 16, 2026 | 425 | Filing |
| Jan 16, 2026 | 425 | Filing |
| Jan 16, 2026 | 8-K | Current Report |
| Jan 16, 2026 | 425 | Filing |